Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study

• Status: Recruiting
• Trial end date: 2021-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yongchang Zhang
• Treatments: Docetaxel

Criteria

Inclusion Criteria:

• 18，Pathologically proven Non squamous non small cell lung cancer

• No-drive gene mutaion (EGFR、ALK、ROS1） by NGS

• Progress after second line

• PS score 0-2

Exclusion Criteria:

• Patients received second line treatment

• Patients received treatment of Anlotinib or Docetaxel

• Patients with contraindication of chemotherapy

• Pregnant or breast feeding women